CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of "Moderate Buy" by Brokerages

CVRx, Inc. (NASDAQ:CVRX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $17.83.

CVRX has been the topic of a number of analyst reports. William Blair upgraded CVRx from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 14th. Lake Street Capital boosted their target price on shares of CVRx from $12.00 to $15.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Canaccord Genuity Group raised their price target on shares of CVRx from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, February 5th. Piper Sandler raised their target price on shares of CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Finally, Craig Hallum upped their price target on CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, January 17th.

CVRx Stock Performance

Shares of NASDAQ:CVRX opened at $13.16 on Tuesday. CVRx has a 12 month low of $6.40 and a 12 month high of $22.45. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $342.69 million, a price-to-earnings ratio of -4.89 and a beta of 1.30. The firm's 50-day moving average is $14.82 and its 200 day moving average is $12.26.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. Research analysts predict that CVRx will post -1.91 EPS for the current year.

Institutional Trading of CVRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in shares of CVRx by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock worth $49,000 after purchasing an additional 1,186 shares during the last quarter. Quarry LP acquired a new position in CVRx in the 4th quarter worth approximately $69,000. MetLife Investment Management LLC purchased a new position in CVRx during the 4th quarter worth approximately $111,000. Wells Fargo & Company MN lifted its stake in CVRx by 86.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,894 shares of the company's stock valued at $113,000 after acquiring an additional 4,115 shares during the period. Finally, Boothbay Fund Management LLC purchased a new stake in shares of CVRx in the 4th quarter valued at $127,000. Institutional investors and hedge funds own 75.27% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.